Supplement
CJC-1295 / Ipamorelin
Growth hormone secretagogues with thin human data.
CJC-1295 and ipamorelin are peptides that stimulate the body's own growth hormone release, often discussed as a stack. We grade CJC-1295 / Ipamorelin C- on evidence and D+ for worth-it at about $80-150 per month.
Evidence
Worth it
Typical cost: $80-150/month
What it does
CJC-1295 and ipamorelin are peptides that stimulate the body's own growth hormone release, often discussed as a stack. Ipamorelin has been through early-phase human trials for other medical indications; CJC-1295 has very limited human data. Neither is approved for longevity, wellness, or performance use, and both are banned in sport.
What the research says
May increase growth hormone pulses
Evidence: emerging. Limited human pharmacology data; no longevity trials.
May improve body composition or recovery
Evidence: weak. No human trials for these outcomes.
DRAFT: some human pharmacology data exists, but no trials support the longevity or performance claims.
Is it worth it?
DRAFT: among the most expensive entries per unit of proven benefit.
Typical cost
$80-150/month
Common form, not a brand recommendation
Dosage contextno established dose
No established human dosage exists for longevity or wellness use.
Safety notes
Not approved for human use. Long-term safety data does not exist. Online products are unregulated. Banned by WADA. Talk to your doctor; do not self-experiment. This page is information, not medical advice.
Longevity Lab Report
CJC-1295 / Ipamorelin news, graded when it happens.
New studies, dose debates, and expert shifts on cjc-1295 / ipamorelin, in one email a week. Free.
Changelog
Last updated 2026-10-15
- 2026-10-15|Peptide/longevity entry added as DRAFT with research-compound framing where applicable.
- 2026-10-15|Dosage context added.
- 2026-10-15|Goal tags added for the stack builder.
- 2026-10-15|Regulatory: Feb 2026 HHS announcement moved CJC-1295 and ipamorelin toward Category 1 (compounding-eligible with prescription). By April 2026 both were formally removed from the Category 2 restricted list. Not FDA approval. Evidence grade unchanged. Source: https://www.ajmc.com/view/5-things-to-know-about-the-fda-s-peptide-reversal